Recall archive / FDA company announcement
Long Grove Pharmaceuticals: Cyclophosphamide for Injection — FDA announcement Jul 24, 2026
Published notice; closure not supplied
A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.
Source date Jul 24, 2026. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- Cyclophosphamide for Injection
- Reason
- Presence of particulate matter identified as steel
- Classification
- Not supplied
- Recalling firm
- Sunny Pharmtech, Inc.
- Quantity
- Not supplied
- Agency-reported status
- Company recall announcement
- Source record identifier
- c7d2516f1f4bd2c7
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | Product Name / Strength | Dosage Form / Package | NDC | Lot Number | Expiration Date; Cyclophosphamide for Injection, USP | 1 g/vial, 50mL vial | 81298-8112-1 | C23019V1 | Oct-2026; Cyclophosphamide for Injection, USP | 1 g/vial, 50mL vial | 81298-8112-1 | C24015V1 | Apr-2027; Cyclophosphamide for Injection, USP | 2 g/vial, 100 mL vial | 81298-8114-1 | V24010V1 | Mar-2027; Online: | Complete and submit the report at www.fda.gov/medwatch/report.htm; Regular Mail: | Download the reporting form at www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a form; complete and return it to the address on the pre-addressed form.; Fax: | Submit the completed form to 1-800-FDA-0178. |
Match all identifying details in the current notice. A brand name alone is not enough.
Product tables from the announcement
These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.
| Product Name / Strength | Dosage Form / Package | NDC | Lot Number | Expiration Date |
|---|---|---|---|---|
| Cyclophosphamide for Injection, USP | 1 g/vial, 50mL vial | 81298-8112-1 | C23019V1 | Oct-2026 |
| Cyclophosphamide for Injection, USP | 1 g/vial, 50mL vial | 81298-8112-1 | C24015V1 | Apr-2027 |
| Cyclophosphamide for Injection, USP | 2 g/vial, 100 mL vial | 81298-8114-1 | V24010V1 | Mar-2027 |
| Online: | Complete and submit the report at www.fda.gov/medwatch/report.htm |
| Regular Mail: | Download the reporting form at www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a form; complete and return it to the address on the pre-addressed form. |
| Fax: | Submit the completed form to 1-800-FDA-0178. |
Announcement retrieved Oct 1, 2026. Official announcement.
Distribution
The affected Product is packaged as 1 g/vial, one 50 mL single-dose vial in a carton (NDC 81298-8112-1) and as a 2 g/vial, one 100 mL single-dose vial in a carton (NDC 81298-8114-1). The affected product was distributed to wholesalers, distributors, hospitals and pharmacies from May 2024 to October 2024 and can be identified using the information below. The three recalled lots (C23019V1, C24015V1, V24010V1) will remain within expiry until October 2026, April 2027, and March 2027, respectively.
No US distribution state could be established from this record. Check the official notice.
Dates in the source
- Fda listing date
- Jul 24, 2026
- Company announcement date
- Jul 24, 2026
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.